Watson Biology (300142.SZ): Freeze-dried herpes zoster virus mRNA vaccine begins phase I clinical trial

Zhitongcaijing · 2d ago

Zhitong Finance App News, Watson Biotech (300142.SZ) announced that the freeze-dried herpes zoster virus mRNA vaccine jointly developed by the company's subsidiaries Beijing Watson Innovation Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., Yuxi Watson Biotechnology Co., Ltd. and Fudan University and Shanghai Blue Magpie Biomedical Co., Ltd. (“Blue Magpie Biology”) has completed preparations for phase I clinical trials. A phase I clinical trial launch meeting was held today to officially launch phase I clinical trials.

The launch of phase I clinical trials of this vaccine is a phased advance in the vaccine development process. The company will actively promote clinical research on the vaccine. If the vaccine is successfully developed, it will further enrich the company's product layout in the field of mRNA vaccines and adult vaccines, laying a solid foundation for the company's long-term steady development.